서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Author

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 42 of 42

Issue DateTitle / Author(s) / CitationFileAltmetrics
2005-04
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib
DOI
2005-10
Reduced dose intensity FOLFOX-4 as first line palliative chemotherapy in elderly patients with advanced colorectal cancer
DOI
2005-12
Phase II trial of low-dose paclitaxel and cisplatin in patients with advanced gastric cancer
DOI
2007-09
Phase II study of low-dose paclitaxel and cisplatin as a second-line therapy after 5-fluorouracil/platinum chemotherapy in gastric cancer
view file
2008-09
Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer
DOI
2009
Chemotherapy-induced transient CEA and CA19-9 surges in patients with metastatic or recurrent gastric cancer
DOI
2009-03
Weight changes after adjuvant treatment in Korean women with early breast cancer

Han, Hye-Suk; Lee, Keun-Wook; Kim, Jee Hyun; Kim, Sung-Won; Kim, In-Ah; Oh, Do-Youn; Im, Seock-Ah; Bang, Soo-Mee; Lee, Jong Seok

Breast Cancer Research and Treatment, Vol.114 No.1, pp.147-153

DOI
2009-08
Patterns of palliative procedures and clinical outcomes in patients with advanced non-small cell lung cancer
DOI
2009-08
Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma
DOI
2009-09
Risk factors for poor treatment outcome and central nervous system relapse in diffuse large B-cell lymphoma with bone marrow involvement
DOI
2010-06
The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer
DOI
2011-01
A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinonna harboring EGFR mutations
DOI
2011-03
Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: Correlation with fluorescence in situ hybridization
DOI
2013-10
Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival
DOI
2014-07
Lamivudine prophylaxis for hepatitis B virus carrier patients with breast cancer during adjuvant chemotherapy
DOI
2014-09
Prediction of survival in terminally ill cancer patients at the time of terminal cancer diagnosis
DOI
2015-03
Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus L-asparaginase as a first-line therapy improves outcomes in stage III/IV NK/T cell-lymphoma, nasal type (NTCL)
DOI
2015-06
Current status of chemotherapy use and clinical outcome in octogenarians with advanced non-small cell lung cancer

Sim, Sung Hoon; Kim, Yu Jung; Kim, Se Hyun; Keam, Bhumsuk; Kim, Tae Min; Lee, Se-Hoon; Kim, Dong-Wan; Heo, Dae Seog; Lee, Jong Seok

Journal of Cancer Research and Clinical Oncology, Vol.141 No.6, pp.1073-1081

DOI
2015-06
A phase I/II trial of second-line chemotherapy with paclitaxel and irinotecan in fluoropyrimidine- and platinum-pretreated patients with advanced gastric cancer
DOI
2015-10
Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations
view fileDOI
2017-04
Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer
view fileDOI
2017-09
Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas
DOI
2017-09
EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release
DOI
2017-11
Diagnosis of secondary peripheral neurolymphomatosis: A multi-center experience
DOI
2017-11
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study
DOI
2018-03
Efficacy of pemetrexed-based chemotherapy in comparison to non-pemetrexed-based chemotherapy in advanced, ALK plus non-small cell lung cancer
view fileDOI
2018-03
Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody
DOI
2018-08
Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy
DOI
2018-08
Low-dose nivolumab can be effective in non-small cell lung cancer: Alternative option for financial toxicity
DOI
2018-11
Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma

Kwon, Hyun Jung; Yang, Jeong Mi; Lee, Jeong-Ok; Lee, Jong Seok; Paik, Jin Ho

Journal of Translational Medicine, Vol.16 No.1, p. 320

DOI
2019-01
Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors
view fileDOI
2019-05
Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report
DOI
2019-10
A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer
DOI
2019-11
The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer
view fileDOI
2020-01
Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies
DOI
2020-07
Immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitors
DOI
2020-12
Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG-LU16-07
DOI
2021-01
Clinical pattern of failure after a durable response to immune check inhibitors in non-small cell lung cancer patients
DOI
2021-02
Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma
DOI
2021-08
A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas
DOI
2021-10
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
DOI
2021-11
Clinicopathologic and Prognostic Significance of Bruton's Tyrosine Kinase Expression in Diffuse Large B-Cell Lymphoma

Han, Yeon Bi; Yang, Jeong Mi; Kwon, Hyun Jung; Lee, Jeong-Ok; Lee, Jong Seok; Paik, Jin Ho

Anticancer Research, Vol.41 No.11, pp.5677-5692

DOI
1